Inotrem's target is tucked in its name: the TREM-1 pathway. This is a new concept of regulating the immune system that aims to restore a typical inflammatory response. The biotech is testing its drug, called nangibotide, against a variety of conditions, including septic shock and severe COVID-19.Inotrem expects to have results from its midstage study against septic shock in mid-2022 and interim data from its late-stage COVID-19 study in the second half of 2022.
Insitro had a busy 2020: It established collaborations with Bristol Myers Squibb in ALS and Gilead Sciences in the liver disease NASH. It also acquired Haystack Sciences, a high-throughput chemistry platform that enables machine-learning-driven molecular design.Northpond Ventures CEO Michael RubinThe first cell-therapy programs have been scientific feats for treating cancer but have also faced commercial and technical challenges.
CEO Philip Johnson told Insider his company planned to refine its vector platform for generating CAR-T cells in the body over the next year, with a goal to begin lab research that would eventually support human testing.Korro is developing an editing platform based on a class of RNA medicine called oligonucleotides. These drugs aim to change a single genetic letter of RNA to help treat diseases.
"Instead of making a permanent change to the DNA, an RNA editor may be better for some diseases," he said.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »